Survivin overexpression has been reported in human malignancies, such as breast (90.2%) [27,28], liver (87%) [29,30], bladder (57.8%) [31,32], stomach (68%) [33,34], oral (>75%) [35,36], and hematological malignancies (68%) [37], and its expression levels were observed to correlate with tumor stage or response to therapy [38]. This evidence concerns the gene BIRC5 and neoplasm.